Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of hepatitis B in China.

Journal of medical virology - 1 Jul 2000

Yao G B

Abstract excerpt

A randomised, multicentre, double-blind, placebo controlled trial was conducted in Chinese patients with chronic hepatitis B to compare the efficacy of once-daily lamivudine and placebo on serum HBV DNA, and to assess the long-term efficacy and safety of lamivudine. Patients received lamivudine 100 mg (n = 322) or placebo (n = 107) once daily for 12 weeks, and were then offered open-label lamivudine treatment for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Antiviral Agents
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B Antibodies

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Lamivudine

Source

Identifiers

PMID: 10861652
DOI: 10.1002/1096-9071(200007)61:3<392::aid-jmv19>3.0.co;2-v

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of hepatitis B in China.PMID 10861652Read ↗

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

Management of viral hepatitis B.Semantic proximity Read ↗

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.Semantic proximity Read ↗

Lamivudine as initial treatment for chronic hepatitis B in the United States.Semantic proximity Read ↗

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.Semantic proximity Read ↗

Chronic hepatitis B virus infection: treatment strategies for the next millennium.Semantic proximity Read ↗

Lamivudine for patients with chronic hepatitis B and advanced liver disease.Semantic proximity Read ↗

[Clinical efficacy of lamivudine in the treatment of chronic hepatitis B].Semantic proximity Read ↗

[Relationship between B virus hepatitis genotypes and therapeutic efficacy in early treatment for chronic hepatitis B by using lamivudine].Semantic proximity Read ↗

HBV genotype B/C and response to lamivudine therapy: a systematic review.Semantic proximity Read ↗

Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.